Goldman Sachs’s Nurix Therapeutics NRIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $6.66M | Buy |
584,519
+77,048
| +15% | +$878K | ﹤0.01% | 2583 |
|
|
2025
Q1 | $6.03M | Buy |
507,471
+44,002
| +9% | +$523K | ﹤0.01% | 2605 |
|
|
2024
Q4 | $8.73M | Sell |
463,469
-49,752
| -10% | -$937K | ﹤0.01% | 2439 |
|
|
2024
Q3 | $11.5M | Buy |
513,221
+48,714
| +10% | +$1.09M | ﹤0.01% | 2140 |
|
|
2024
Q2 | $9.69M | Sell |
464,507
-28,159
| -6% | -$588K | ﹤0.01% | 2113 |
|
|
2024
Q1 | $7.24M | Buy |
492,666
+210,766
| +75% | +$3.1M | ﹤0.01% | 2300 |
|
|
2023
Q4 | $2.91M | Sell |
281,900
-81,626
| -22% | -$842K | ﹤0.01% | 2965 |
|
|
2023
Q3 | $2.86M | Buy |
363,526
+40,878
| +13% | +$321K | ﹤0.01% | 2859 |
|
|
2023
Q2 | $3.22M | Sell |
322,648
-218,062
| -40% | -$2.18M | ﹤0.01% | 2887 |
|
|
2023
Q1 | $4.8M | Sell |
540,710
-80,938
| -13% | -$719K | ﹤0.01% | 2584 |
|
|
2022
Q4 | $6.83M | Sell |
621,648
-203,431
| -25% | -$2.23M | ﹤0.01% | 2399 |
|
|
2022
Q3 | $10.8M | Buy |
825,079
+493,236
| +149% | +$6.43M | ﹤0.01% | 2069 |
|
|
2022
Q2 | $4.2M | Buy |
331,843
+16,177
| +5% | +$205K | ﹤0.01% | 2805 |
|
|
2022
Q1 | $4.42M | Buy |
315,666
+7,179
| +2% | +$101K | ﹤0.01% | 2896 |
|
|
2021
Q4 | $8.93M | Buy |
308,487
+183,772
| +147% | +$5.32M | ﹤0.01% | 2365 |
|
|
2021
Q3 | $3.74M | Sell |
124,715
-156,137
| -56% | -$4.68M | ﹤0.01% | 2992 |
|
|
2021
Q2 | $7.45M | Sell |
280,852
-66,241
| -19% | -$1.76M | ﹤0.01% | 2487 |
|
|
2021
Q1 | $10.8M | Buy |
347,093
+187,544
| +118% | +$5.83M | ﹤0.01% | 2153 |
|
|
2020
Q4 | $5.25M | Buy |
+159,549
| New | +$5.25M | ﹤0.01% | 2441 |
|